Ranolazine: an anti-anginal drug with further therapeutic potential. - Wikidata - wikimedia - TriplyDB

Ranolazine: an anti-anginal drug with further therapeutic potential.

Ranolazine: an anti-anginal drug with further therapeutic potential.

http://www.wikidata.org/entity/Q37707393

about

Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model.

P2860

Q26995558-6145EBB4-EA3A-40A5-823D-7C79C4B20D43 Q38547436-E4246D84-1693-49A8-96D7-B5E4193EE108 Q48299852-054EED92-C22F-4669-ACBB-7686E00FDB01

P2860

Ranolazine: an anti-anginal drug with further therapeutic potential.

http://www.wikidata.org/entity/Q37707393

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ranolazine: an anti-anginal drug with further therapeutic potential.

@en

Ranolazine: an anti-anginal drug with further therapeutic potential.

@nl

type

label

Ranolazine: an anti-anginal drug with further therapeutic potential.

@en

Ranolazine: an anti-anginal drug with further therapeutic potential.

@nl

prefLabel

Ranolazine: an anti-anginal drug with further therapeutic potential.

@en

Ranolazine: an anti-anginal drug with further therapeutic potential.

@nl

P1433

Q37707393-7950F46C-30FA-4AF3-9D62-35B2310682F2

P1476

Q37707393-D1C35178-4C4F-4A47-A284-BDBCCAE1C2F5

P2093

Q37707393-056CD866-85D3-426A-8513-2987FF5D97F2

Q37707393-B499326D-6766-4E94-BD45-36557BF72D5B

P2860

Q37707393-03E2844A-4489-4028-A203-28B134A3B1C4

Q37707393-0B398D8A-56D4-4E57-90E5-B074387BA3A3

Q37707393-0D7A8099-B92D-4B5D-82CB-D58F50601E2E

Q37707393-1A0B4AF2-955F-4B7F-8F8B-0B3540563F60

Q37707393-1C4B37ED-E7D2-449F-9538-54FA4047E43E

Q37707393-1F9DEFB9-B619-4443-8F79-9359FE993CF4

Q37707393-2649529C-EA0A-4B0C-9299-528B3690A67A

Q37707393-29641B19-0721-415D-81BC-66A9534D3482

Q37707393-2E6AF54C-A118-4BBF-8190-91CA63587A0A

Q37707393-3A401EB5-C948-479A-83AF-F3ECE631A939

P304

Q37707393-BBAE9E89-37F7-4141-A5FF-857CD9BFA728

P31

Q37707393-94D4C100-ED1C-4D9F-92AD-2B83B80C0711

P356

Q37707393-6FEF43AB-B98D-4CEF-9ADA-CDD9EBFF8ADD

P433

Q37707393-9721815F-B529-40FA-82E0-6798B64AF212

P478

Q37707393-3B1050A3-FBEB-4EAD-B9FC-E2A4D89F59E9

P577

Q37707393-3FC53F98-1B61-42E6-A387-3EB5756BA832

P698

Q37707393-EB6020CC-D456-4E02-A777-09714778642E

P356

P1433

Expert Review of Cardiovascular Therapy

P1476

Ranolazine: an anti-anginal drug with further therapeutic potential.

@en

P2093

Robert A Kloner

http://www.w3.org/2001/XMLSchema#string

Thorsten Reffelmann

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.

Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.

Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure.

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.

Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.

Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts.

P304

319-329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERC.09.178

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20222810

http://www.w3.org/2001/XMLSchema#string